抗血管内皮生长因子药物及其发展：在眼部疾病中的治疗意义
Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.
作者信息
Kaiser Peter K
机构信息
Cleveland Clinic, Cleveland, OH, USA.
出版信息
Am J Ophthalmol. 2006 Oct;142(4):660-8. doi: 10.1016/j.ajo.2006.05.061.
PURPOSE
To provide an overview of angiogenesis and vascular endothelial growth factor (VEGF) and discusses the development approach, safety, and efficacy results of current and emerging anti-VEGF therapies for ocular diseases.
DESIGN
Analysis of literature and current clinical trials of antiangiogenic agents for age-related macular degeneration (AMD).
METHODS
Literature review.
RESULTS
There are several novel antiangiogenic molecules that target vascular endothelial growth factor and are being used in the management of AMD. Large scale, Phase III trials have shown promising results in improving vision in this devastating disease.
CONCLUSIONS
Therapies that target VEGF have shown tremendous promise as treatments for AMD.
目的
概述血管生成和血管内皮生长因子（VEGF），并讨论用于眼部疾病的现有及新兴抗VEGF疗法的研发方法、安全性和疗效结果。
设计
对用于年龄相关性黄斑变性（AMD）的抗血管生成药物的文献及当前临床试验进行分析。
方法
文献综述。
结果
有几种靶向血管内皮生长因子的新型抗血管生成分子正用于AMD的治疗。大规模III期试验已显示出在改善这种致盲性疾病的视力方面取得了有前景的结果。
结论
靶向VEGF的疗法已显示出作为AMD治疗方法的巨大前景。
Zotero 插件